Stem Cell Treatment Clinics: A 2026 Patient Vetting Checklist

Introduction: Why Vetting a Stem Cell Clinic Is Unlike Any Other Medical Decision

Most medical decisions take place within a system of built-in safeguards. Licensed pharmacies dispense approved drugs, hospitals answer to accreditation bodies, and insurers scrutinize what they cover. Stem cell clinics often operate outside that system, so the patient may be the only safeguard left.

The scale of the problem is substantial. Researchers estimate that more than 2,000 U.S. firms sell unproven, non-FDA-approved cellular products. A peer-reviewed count published in Cell Stem Cell found that as of March 31, 2021, 1,480 U.S. businesses were operating 2,754 clinics that marketed purported stem cell therapies directly to consumers. California (347), Florida (333), and Texas (310) together accounted for more than one-third of all U.S. clinics. These businesses are not fringe operations hidden in back alleys. They operate out of strip malls, wellness centers, and professional offices in major metropolitan areas, often backed by well-designed websites.

In 2026, Robert F. Kennedy Jr., while serving as health secretary, said on a podcast that he had received unproven stem cell treatments in the Caribbean for a throat condition. The episode shows that wealth, access, and public visibility do not protect anyone from entering an unregulated treatment environment. Every prospective patient needs a reliable vetting process.

This article does not rank “best clinics” or repeat a generic list of warning signs. It offers one verification framework that connects a clinic’s regulatory status to evidence patients can check themselves. Readers will come away with a four-part evaluation built on:

1. Institutional Review Board (IRB) oversight
2. ClinicalTrials.gov registration
3. ISO/GMP laboratory certification
4. Closed vs. open cell-processing systems

The Regulatory Foundation: Three Categories Every Clinic Falls Into

Every other vetting step depends on the clinic’s regulatory category, which determines what documentation should exist, who should be overseeing the treatment, and whether the patient should be paying at all. Every stem cell offering falls into one of three categories:

• FDA-approved therapies
• Investigational treatments offered within a legitimate clinical trial under an active Investigational New Drug (IND) application
• Unapproved and unlicensed interventions

Category 1: FDA-Approved Stem Cell Therapies

As of 2026, the only FDA-approved therapy using stem cells is hematopoietic stem cell transplantation. It usually takes the form of a bone marrow or peripheral blood stem cell transplant, and the cells can also come from umbilical cord blood. These procedures treat specific blood and immune disorders in established medical centers.

A small number of other cell and gene therapies have FDA approval for narrowly defined indications. Patients should check current tracking resources, such as The Niche’s regularly updated list of FDA-approved cell and gene therapies, instead of relying on what a clinic’s marketing says.

The practical takeaway is simple. If a clinic offers generic “stem cell therapy” for joint pain, anti-aging, neurological conditions, or autoimmune disease, that treatment has no FDA approval and does not belong in this category.

Category 2: Legitimate Investigational Treatments

Legitimate clinical trials test new treatments under defined safeguards. A real investigational study typically has:

• An active IND application on file with the FDA
• IRB oversight for ethical and safety review
• Registration on ClinicalTrials.gov
• No charge to participants for the experimental treatment itself

A leading ophthalmology researcher has identified cost as one of the clearest red flags. Patients should never have to pay for an emerging treatment in an FDA-authorized clinical trial. If a clinic charges a fee for a stem-cell-derived treatment and calls it trial participation, something is wrong.

Patients are most often misled about this category. Clinics frequently use terms like “study,” “protocol,” or “research program” to suggest trial status when no legitimate trial infrastructure exists.

Category 3: Unapproved and Unlicensed Interventions

Most marketed “stem cell” treatments for orthopedic, neurological, autoimmune, and anti-aging purposes fall into this category. These products have not been through the FDA approval process, and the clinics selling them have no active trial authorization.

Regulators treat these products as subject to enforcement. In 2024, a federal appeals court upheld the FDA’s authority to regulate these therapies, confirming that clinics cannot escape oversight simply by calling a procedure the “practice of medicine.” Since December 2018, the FDA has issued at least 400 letters to manufacturers and health care providers that may be offering violative stem cell or related products, including 46 Untitled Letters involving violative human cells, tissues, and cellular and tissue-based products (HCT/Ps). Those numbers show how widespread non-compliance remains.

The Four-Part Verification Framework: What Patients Can Check Themselves

The guidance from the International Society for Stem Cell Research (ISSCR), the FDA, and international quality standards bodies is authoritative, but it is dense and difficult for most patients to apply. The framework below turns those concepts into four items any patient can check before booking a consultation.

One principle governs all four: each criterion must be independently confirmable. A statement from clinic staff, a badge on a website, or a line in a brochure is a claim. Verification means confirming that claim through a source the clinic does not control.

Criterion 1: Institutional Review Board (IRB) Oversight

An IRB is an independent committee that reviews research involving human subjects. It evaluates whether risks are reasonable, whether informed consent is adequate, and whether participants are protected. When an IRB is involved, the treatment is being conducted under ethical and safety review rather than sold as an unsupervised commercial product.

Verification steps:

• Ask for the full name of the IRB overseeing the treatment.
• Ask which accreditation body, if any, recognizes that IRB.
• Independently confirm that the IRB is a recognized, established entity and not a committee created by, owned by, or financially tied to the clinic itself.
• Request the IRB approval documentation for the specific protocol being offered.

The red-flag pattern: Some clinics advertise “IRB-approved” status to imply FDA sanction. IRB approval alone does not equal FDA authorization. A clinic can have IRB sign-off and still be selling an unapproved product outside any legitimate IND. Patients should treat “IRB-approved” as the beginning of the inquiry, not the end.

Criterion 2: ClinicalTrials.gov Registration

Legitimate clinical trials involving human subjects are generally required to register on ClinicalTrials.gov, a public database maintained by the U.S. National Library of Medicine. Registration creates a searchable record of the study’s sponsor, purpose, locations, status, and eligibility criteria.

How to search the registry:

1. Search by the sponsor or clinic name the provider uses.
2. Search by the condition being treated (for example, “knee osteoarthritis” or “multiple sclerosis”) combined with “stem cell” or “mesenchymal.”
3. Filter by location to confirm the clinic’s address appears as a study site.
4. Check the recruitment status (“Recruiting,” “Active,” “Completed”) and confirm the trial is currently enrolling.
5. Ask the clinic for the trial’s NCT number and look it up directly.

Registration and legitimacy are not the same thing. Registration does not guarantee that a trial is well designed or ethically run, and some questionable operations have registered studies to appear credible. The absence of any registration for a claimed “clinical trial,” however, is a serious red flag that should end the conversation.

Criterion 3: ISO/GMP Laboratory Certification

The laboratory that processes a patient’s cells matters as much as the clinic that injects them. Contamination, inadequate donor screening, and inconsistent processing all happen at the lab level.

Two kinds of credentials are especially relevant:

• ISO certification indicates that a facility follows internationally recognized quality management standards.
• GMP (Good Manufacturing Practice) compliance indicates that products are manufactured under controlled conditions with documented procedures for sterility, consistency, and safety testing.

Verification steps:

• Ask the clinic to identify the specific laboratory that processes or supplies the cells.
• Request copies of the lab’s certifications, including the certifying body and certificate number.
• Verify the certification against the certifying body’s public records where available.
• Ask whether the lab has undergone independent audits, and when.

A documented case shows what is at stake. The FDA warned a California-based stem cell company for selling unapproved products manufactured without proper safety measures, including failure to screen for HIV and hepatitis. At least 13 people were hospitalized with serious bacterial infections across Texas, Arizona, Kansas, and Florida. Inadequate lab standards cause real injuries.

Criterion 4: Closed vs. Open Cell-Processing Systems

How tissue is handled after collection affects both safety and regulatory status.

• Closed systems keep tissue within sealed equipment throughout processing, which minimizes exposure to the environment and reduces contamination risk.
• Open systems expose tissue to the environment during handling and often involve greater manipulation. They carry higher infection risk and draw greater regulatory scrutiny.

Manipulation also matters under the FDA’s framework. Products that are more than minimally manipulated, meaning their original biological characteristics have been altered, generally require FDA approval regardless of how a clinic describes them. A clinic’s claim that its procedure is “minimally manipulated” and therefore exempt deserves careful scrutiny, because the regulatory category depends on what actually happens to the cells.

A simple question patients can ask:

“Is my tissue processed in a closed system, and can you show documentation of the equipment and protocol used?”

A legitimate provider should be able to answer clearly and produce supporting records.

Learning from Documented Harm: What Happens When Vetting Fails

The Florida macular degeneration case is among the most cited examples of harm from unregulated stem cell treatment. A clinic gave eye injections to three patients with age-related macular degeneration using cells derived from their own fat tissue. The patients suffered severe and permanent vision loss. Their injuries became central to the FDA’s federal court case against the clinic, which ultimately affirmed the agency’s authority to regulate these products.

That case fits a broader pattern documented in peer-reviewed research. Even with significant underreporting of adverse events, researchers have identified hundreds of patients who have suffered physical injury, emotional distress, or financial harm from unproven stem cell treatments. Charges varied widely, and treatments were often presented misleadingly as participation in a clinical trial.

Clinic marketing is no substitute for verification. A 2020 study of clinic websites found that 96% displayed at least one misstatement, and the average site contained between four and five misstatements. A polished website, persuasive patient testimonials, and confident medical language prove nothing about safety or efficacy.

The Federal Trade Commission has taken its own enforcement actions, stopping clinics from making deceptive claims that stem cells could treat conditions such as Parkinson’s disease, autism, and macular degeneration. Clinics that make these claims face scrutiny from more than one federal regulator.

A Critical Distinction: PRP vs. “Stem Cell” and Exosome Products

Orthopedic and pain clinics often offer several “regenerative” options, and patients should not treat them as interchangeable.

Platelet-rich plasma (PRP) is not FDA-approved for most orthopedic uses, but it is widely and legally offered off-label. A substantial body of orthopedic clinical research supports it, though results vary by condition.

“Stem cell” and exosome products marketed for orthopedic or pain conditions are a different matter. They have not been approved by the FDA for these uses, and very little high-quality randomized evidence supports them.

Some clinics deliberately blur this line. A provider may cite PRP’s legitimate evidence base and then offer an unproven cell or exosome product in the same visit, sometimes bundled into one “regenerative package.” Patients should ask exactly which product is being administered, what it contains, and what evidence supports that specific product for their specific condition.

Putting It Together: A Step-by-Step Vetting Checklist

Patients can follow this sequence before contacting any clinic and during early conversations with providers:

1. Identify the regulatory category claimed. Determine whether the clinic presents the treatment as FDA-approved, investigational (trial-based), or neither. Compare that claim against current FDA approval lists.
2. Verify IRB oversight. Obtain the IRB’s name, accreditation, and approval documentation, and confirm independently that the IRB is not affiliated with the clinic.
3. Search ClinicalTrials.gov. If the clinic claims trial status, locate the NCT number and confirm the study, sponsor, site location, and recruitment status.
4. Request lab certification documents. Identify the processing lab, obtain ISO/GMP documentation, and verify it with the certifying body.
5. Confirm closed vs. open processing. Ask for documentation of the equipment, protocol, and degree of cell manipulation.
6. Cross-check marketing claims against FDA and FTC enforcement records. Search the clinic’s name, owners, and product suppliers in publicly available FDA warning letter databases and FTC enforcement announcements.

Complementary resource: The ISSCR’s patient guide to stem cell treatments, last updated in February 2024, lists official questions patients should ask before considering investigational or unproven treatments. State health agencies, including the Connecticut Department of Public Health, direct patients to these materials. Using the ISSCR questions alongside this checklist gives patients an internationally recognized reference point.

Document everything in writing. Request answers by email or written correspondence and keep copies. If a clinic is reluctant, evasive, or vague on any of the six steps, treat that as a disqualifying signal.

For medical tourism: The Harvard Stem Cell Institute has warned that “thousands, if not tens of thousands” of people have traveled to clinics in the U.S., Mexico, China, India, the Caribbean, Latin America, and former Soviet states for unproven interventions. The same framework applies abroad, with two additional priorities:

• Verify whether the destination country’s regulatory approval is equivalent in rigor to FDA review, rather than assuming any local license is sufficient.
• Insist on evidence of independent lab audits and GMP compliance. Lower prices abroad may reflect lower costs of operation, but they may also mean less oversight, and patients need to find out which.

When to Walk Away: Non-Negotiable Disqualifiers

Some answers should end the evaluation immediately. Patients should walk away from any clinic that:

• Cannot produce IRB documentation for the treatment being offered
• Has no ClinicalTrials.gov record for a treatment described as a clinical trial
• Cannot provide verifiable lab certification from a recognized certifying body
• Refuses to disclose whether tissue is processed in an open or closed system
• Asks the patient to pay to participate in what it describes as a clinical trial

The problem is not going away. STAT News reported in September 2026 that the FDA’s Center for Biologics Evaluation and Research (CBER) continues to take enforcement actions against unproven stem cell clinics and their marketing practices. Regulators still consider this an active and growing concern.

The burden of proof belongs to the clinic, not the patient. A legitimate provider expects these questions and has the documentation ready. A patient who asks for evidence is being diligent, not difficult.

Conclusion: Turning Regulatory Complexity Into a Confident Decision

Unproven stem cell treatments can cost patients their savings, their health, and their trust in medicine. The documented record of blindness, serious infections, and misleading trial claims justifies a rigorous, document-based vetting process. Testimonials and marketing language cannot replace it.

The four-part framework of IRB oversight, ClinicalTrials.gov registration, ISO/GMP laboratory certification, and closed-system processing works for any clinic, whether it sits in a nearby city or across an ocean. Combined with a clear understanding of the three regulatory categories, it lets patients tell legitimate medicine apart from commercial speculation.

The framework draws on primary sources: FDA enforcement records, FTC actions, ISSCR guidance, and peer-reviewed harm data. It turns them into questions patients can answer before they ever book a consultation.

Next Step: Get Clarity Before You Commit

Patients can use this checklist as a working document during their research and clinic outreach. Recording each clinic’s answers side by side makes gaps, inconsistencies, and evasions much easier to spot.

For more information, visit adiamed.com.

Informed questions asked before a consultation are the strongest protection against unproven, high-risk treatments.